A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

Phase 1 Terminated 37 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.

Timeline

Start: 2004-12
Primary completion: 2007-08
Completion: 2007-08

Outcome

Outcome not reported

Stopped: “See Detailed Description”

Publications

Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AG-24322	Small molecule	—	Intravenous